a Stanford University; Stanford, CA USA.
Hum Vaccin Immunother. 2014;10(8):2295-302. doi: 10.4161/hv.29233.
Oral immunotherapy (OIT) is an emerging new therapy for food allergy. With multiple small exploratory trials and some large randomized-controlled phase 2 trials recently published and under way, there is a clear progress and interest toward making this a treatment option for patients suffering from food allergies. However, there are still many questions to be answered and parameters to fine-tune before OIT becomes an accepted option outside of the research setting. This review covers the main milestones in the development of OIT for food allergy and further discusses important specific issues that will have direct impact on its clinical application. More specifically, previous publications showing evidence for the induction of tolerance are specifically reviewed and varying safety, tolerability and efficacy parameters from previous reports are also discussed.
口服免疫疗法(OIT)是一种新兴的食物过敏治疗方法。随着最近发表的多项小型探索性试验和一些大型随机对照 2 期试验的开展,人们对将其作为治疗食物过敏患者的一种选择的兴趣越来越大。然而,在 OIT 在研究环境之外成为一种公认的选择之前,仍有许多问题需要回答,还有许多参数需要调整。这篇综述涵盖了食物过敏 OIT 发展的主要里程碑,并进一步讨论了将直接影响其临床应用的重要具体问题。更具体地说,本文特别回顾了先前发表的证明诱导耐受的证据,并讨论了来自先前报告的不同安全性、耐受性和疗效参数。